Clinical guidelines are recommendations based on systematic identification and synthesis of the best available scientific evidence. The National Health and Medical Research Council (NHMRC) has published standards for guideline development.
According to the NHMRC standards, guideline development must be a transparent and independent process, with full disclosure of any potential competing interests.
Australian guidelines for prevention of venous thromboembolism have been published by an autonomous group. Several features of the processes used to produce and distribute these guidelines, such as pharmaceutical sponsorship, do not meet NHMRC endorsement standards.
The guidelines may overstate the need for thrombo-prophylaxis in medical patients, and thus expose some patients to an unnecessary risk of bleeding complications.
Despite this, these guidelines have been taken up avidly by national and state bodies responsible for safety and quality in health care, and mandated national application has been proposed.
In a recent article in the Journal, I questioned the scientific and clinical basis for routine medical thromboprophylaxis using low molecular weight heparin (LMWH) or unfractionated heparin.1 Such a policy risks a benefit–hazard (major bleeding) ratio that is less than unity.2 In this article, I discuss how Prevention of venous thromboembolism: best practice guidelines for Australia and New Zealand, fourth edition (henceforth, the Guidelines),3 have achieved widespread dissemination and acceptance in Australia despite being produced by an autonomous group and not having been peer-reviewed. Two major factors appear likely here — first, the Guidelines are sponsored by a global pharmaceutical company and are professionally marketed; second, clinical quality and safety bodies appear to have adopted them “on trust”, without further independent assessment. I believe there needs to be greater transparency of all aspects of guideline production, and that current standards need to be more closely adhered to.
The Guidelines are written by the Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism.3 The Working Party comprises 14 eminent and appropriately qualified haematologists, physicians and surgeons from Australia and New Zealand, although how they came together as a group or whether the Working Party belongs to any parent organisation is not stated. The Guidelines are published as a booklet and can also be found on third-party websites,4,5 but neither the Guidelines nor the Working Party have a specific website. Unlike similar overseas guidelines on the prevention of venous thromboembolism (VTE)6,7 which have been published in peer-reviewed journals, these Guidelines have only been published in independent booklet form. Examples of other guidelines published in peer-reviewed journals include a position statement on warfarin reversal (which includes several members of the current Working Party as authors),8 and guidelines in other areas of clinical medicine.9-11
There are three main methods by which clinical guidelines can achieve status within the medical community. First, the National Health and Medical Research Council (NHMRC) has produced a guide for the development of guidelines,12 and will consider endorsing any externally produced guidelines according to its standards of scientific merit, sponsorship and conflicts of interest. The Guidelines have not been so endorsed. Second, guidelines can be submitted for assessment and publication in a peer-reviewed journal. This has not occurred with the Guidelines to date. Third, guidelines can be endorsed by a recognised medical authority, often in the form of a position statement of the relevant learned society, which may also be disseminated by publication in a peer-reviewed journal. This has not happened with the Guidelines.
The Working Party states that it is “proud” to be affiliated with the International Union of Angiology and the Australasian Society of Thrombosis and Haemostasis,3 but it does not claim endorsement by any organisation. The nature of the affiliation is not described, and the public websites of these organisations do not refer to the Guidelines or the Working Party.13,14
The current (fourth) edition of the Guidelines acknowledges commercial sponsorship by a “non directed” grant from Sanofi-Aventis, the manufacturer of the LMWH enoxaparin.3 This implies that the Working Party receives funds from the sponsor but retains editorial discretion, although the precise funding mechanism is uncertain. Some of the Working Party members have disclosed additional financial associations with Sanofi-Aventis in an editorial previously published in this Journal.15 No acknowledgement of sponsorship was present in the third edition of the Guidelines, so the sponsorship is either new or previously unannounced. The provisions for medical prophylaxis are the same in both editions.
Although copyright to the Guidelines is held by the Working Party, the booklets are distributed free of charge by Sanofi-Aventis representatives at meetings sponsored by the company, and are not readily available via other sales outlets. Within the Guidelines, the sponsor’s product is consistently mentioned as the first of the two LMWHs currently available in Australia. This may reflect the unique registration with the Therapeutic Goods Administration for medical prophylaxis enjoyed by enoxaparin in Australia. Sanofi-Aventis is also a major sponsor of the “affiliated”3 International Union of Angiology, listed as such on the Union’s website.13
The Guidelines are published by Health Education and Management Innovations (HEMI) Australia Pty Ltd, which is incorporated in New South Wales. In a shared website,16 HEMI describes itself as providing “a ‘broker’ service between clinicians and the healthcare industry”. At the time of writing, the company had no telephone number listed in the White Pages, no easily accessible public address, no dedicated website detected by Google, and used a generic email address (email@example.com). HEMI’s company details, available from the Australian Securities and Investments Commission, reveal that a member of the Working Party is a HEMI director and shareholder. The above relationships suggest that, in effect, the Working Party publishes its own Guidelines via a company that is part-owned by a member, with essential costs met by the acknowledged “non directed” grant from Sanofi-Aventis.
HEMI has published several booklets in the field of thrombosis and thromboprophylaxis.3,17,18 One of these is subtitled “best practice international guidelines” for the prevention of VTE.17 It has no named authors, has very similar content to the Working Party’s Guidelines, claims endorsement by the International Union of Angiology and is also sponsored by Sanofi-Aventis.17 Readers of this publication are referred to HEMI for details of authorship and copyright, but, as yet, I have received no response to a request for information on these points.
In addition to direct sponsorship of the Working Party, Sanofi-Aventis has funded the public relations company Fleishman-Hillard to help market enoxaparin.19 This marketing process has been reported to include “the release of hospital guidelines, the publication of a research study in Lancet, and a summit in Sydney”.19
The need for thromboprophylaxis has received ready coverage in the media. For example, in an article in the Sydney Morning Herald entitled “Simple jab can cut blood clot deaths”, a member of the Working Party claimed “All patients should be given the prophylaxis. It’s very cheap, it’s very safe and it’s very effective”.20 The same article states that the injection should be “mandatory” and claims that 10 000 deaths per year will be “combat[ed]” by prophylaxis. Similar articles21,22 followed a recent research article23 and invited editorial15 in this Journal.
In furtherance of its aims, the Working Party organised a “summit” at the Westin Hotel, Sydney, on 2 May 2008 on behalf of itself and another group called “ACTION on VTE” (Australian Coalition on Thrombosis for Improving Outcomes Nation-wide on VTE). A report of the summit was published the following day in major daily newspapers, again under dramatic headlines such as “Blood clots cost Australia $1.72 billion”.24-27 Invitations to the summit (which did not feature any provision for presentation of independently submitted papers) did not state whether the meeting was sponsored, but the Coalition’s secretariat was HEMI, and acknowledgements of registration were sent under the letterhead of and “on behalf of” Sanofi-Aventis. The genesis of the concept of an Australian “Coalition” is uncertain, but a “Coalition to Prevent Deep-Vein Thrombosis”, sponsored by Sanofi-Aventis, exists in the United States.28 This group also conducts meetings in hotels and has involved special interest groups, the public, and politicians.
ACTION on VTE plans include mandatory reporting of VTE risk assessment, incidence and readmission rates under the Australian Health Care Agreement. Thus, like its American counterpart, the Coalition seeks to mandate a discretionary element of medical practice by deployment of political authority. In promotional material for the summit, it was claimed that “a delay in ACTION on VTE until the next round of Healthcare Agreements in five years time could contribute to up to 50,000 preventable deaths [a repeat of the 10 000 per year quoted above] from pulmonary embolism in Australia”. This high figure was not referenced and would seem more likely to be an estimate of the total annual deaths from VTE in Australia.23 A report by Access Economics, commissioned by the Working Party and released at the Sydney summit provides VTE incidence data based on Australian Institute of Health and Welfare coding statistics that include cerebral infarction due to embolism of precerebral and cerebral arteries, arterial embolism, and thrombosis.29 As these non-venous phenomena account for 26% of the total VTE,29 the report may overestimate VTE incidence by up to 35%. The report does not state its funding source, but an article in the BMJ reported that “the summit and the report were both part-funded by Sanofi-Aventis”, and that the summit was “organised with help from Fleishman-Hillard”.19
NSW Health resolved to distribute the fourth edition of the Guidelines to NSW medical practitioners in a form that erases the reference to the commercial sponsorship.30 This arrangement was formally announced in September 2008.31 NSW Health was reported as seeing no problem with obscuring the fact of commercial sponsorship because in its view, the Guidelines have been produced by experts.30
The Guidelines have been reproduced or cited on the websites of various national and state bodies responsible for quality assurance in health care. These include the National Institute of Clinical Studies (NICS; an institute of the NHMRC),32 and the Australian Commission on Safety and Quality in Health Care.33 The Commission has indirectly supported the Guidelines by virtue of its “Stop the Clot” campaign in residential aged care facilities, which has received the support of the federal government. On the NICS website, the main evidence for emphasising thromboprophylaxis is given in three “commissioned” papers34 that used an investigative tool (analysis of coded hospital morbidity data) that is subject to admitted bias35 and is known to be unreliable in related research.36 Like the Guidelines, these reports have not been published in a peer-reviewed journal. Similarly, the NSW Therapeutic Advisory Group37 and the Office of Safety and Quality in Healthcare38 in Western Australia advocate adoption of and cite the Guidelines, as a clinical indicator and clinical quality assurance standard respectively.
As far as I am aware, no group justifies its choice, but the most likely explanation is that the Guidelines have been accepted without question by virtue of the presumed unimpeachability of the members of the Working Party, similar to the reasoning offered by NSW Health to justify distributing the Guidelines with the sponsorship details removed. Alternatively, the lead of one such organisation may simply have been copied by the others. Commendably, NICS is reviewing and continuing to develop its thromboprophylaxis guidelines.39 The reviewing committee includes two members of the Working Party in a representative capacity.40
I am concerned that the Guidelines overstate the need for pharmacological prophylaxis in medical patients, and that patients at low risk of VTE will be exposed unnecessarily to the risk of bleeding complications. The Working Party’s dichotomous system for defining medical patients for VTE risk is problematic because the absolute risk threshold between low risk and high risk is not stated. In the Guidelines, patients are deemed to be at “high” risk and requiring anticoagulant prophylaxis if they have any of seven features (six specified disease states, or age > 60 years).
The two large trials of LMWH — MEDENOX (Prophylaxis in Medical Patients with Enoxaparin)41 and PREVENT (Prevention of Recurrent Venous Thromboembolism)42 had more stringent trial selection criteria for medical thromboprophylaxis than the Guidelines (Box). One of the conditions listed in the Guidelines as a high-risk condition (ischaemic stroke) was an exclusion criterion in the trials. These trials included patients who had an additional risk factor for VTE unless they had congestive heart failure or severe respiratory disease. The omission of these factors from the Guidelines means that they apply to a larger subpopulation of medical patients than was entered into the trials, and thus define a medical patient population for prophylaxis that is at lower average risk of VTE than the trial populations. This decreases the benefit–hazard ratio and degrades cost-effectiveness. No justification for the dichotomous grouping, or for deviating from the trial evidence base, is provided. The Guidelines state that “the relative risks for bleeding versus VTE must be considered when commencing anticoagulation”, but neither the likely bleeding risk nor guidance on how it should be “considered” is provided.
This article describes commercial and working links between various parties in the field of thromboprophylaxis in Australia. In summary, the Guidelines were written by a Working Party of experts, but sponsored by the manufacturer of a drug advocated in the guidelines. They were not externally reviewed or published in a peer-reviewed journal, and appear to have become widely accepted and found their way into secondary guidelines promoted by national and state bodies responsible for clinical safety and quality without further assessment by these bodies. There is a business link between one of the members of the Working Party and the publisher of the Guidelines. Promotional activities associated with the dissemination of the Guidelines have been funded by the sponsor and resemble similarly funded activities by the same sponsor overseas. The Guidelines were initially only available from the sponsor, although they have subsequently been made available on third-party websites. I believe that some scientific aspects of the Guidelines need further clarification.
It is easy to see how national and state quality assurance bodies have become enthusiastic advocates of VTE prophylaxis, if they have received a potentially erroneous impression that tens of thousands of hospital patients will die unnecessarily each year without it. Quality and safety organisations are not primary medical bodies, and they may be inclined to accept clinical advice from external sources of “experts” without further critical assessment. In this case, the ready availability of apparently authoritative guidelines, and frequent publicity of the topic in the lay press, appear to have created a “bandwagon” effect in favour of widespread adoption of the guidelines. However, such automatic adoption of non-peer-reviewed clinical guidelines intended for national application by taxpayer-funded bodies with a duty to improve the quality and safety of medical treatment may not be in the public interest.
Selection and exclusion criteria from two trials of LMWH thromboprophylaxis in medical patients compared with the eligibility criteria for thromboprophylaxis according to the Australia and New Zealand Working Party Guidelines3
Pregnancy, lactating women, women not using contraception; stroke or major surgery within 3 months; iodine sensitivity; thrombophilia; creatinine > 150 μmol/L; intubation; HIV infection; blood pressure > 200/120 mmHg; active peptic ulcer; bacterial endocarditis; increased haemorrhagic risk, including a requirement for anticoagulants or use of anticoagulants for > 48 hours.
Acute infection with septic shock; acute rheumatic disorder including acute lumbar pain or sciatica or vertebral compression; acute arthritis or rheumatoid arthritis of the legs; or inflammatory bowel disease
Acute coronary syndrome within 1 month; surgery or invasive procedure within 1 month or planned within 2 weeks; bacterial endocarditis; immobilised lower limb because of cast or fracture; stroke within 3 months; high bleeding risk; platelet count < 100 × 109; heparin or LMWH given for > 48 hours before randomisation; contraindication to heparin; creatinine > 200 μmol/L; hepatic insufficiency or active hepatitis; pregnancy or breastfeeding; life expectancy < 1 month.
LMWH = low molecular weight heparin. MEDENOX = Prophylaxis in Medical Patients with Enoxaparin. LOS = length of stay. CCF = congestive cardiac failure.
- 1. Millar JA. Rational thromboprophylaxis in medical inpatients: not quite there yet. Med J Aust 2008; 189: 504-506. <MJA full text>
- 2. Millar JA. Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit:hazard ratio. Intern Med J 2009. In press.
- 3. Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. Prevention of venous thromboembolism: best practice guidelines for Australia and New Zealand. 4th ed. Sydney: Health Education and Management Innovations, 2007.
- 4. Royal Australasian College of Surgeons. Resources for surgeons: venous thromboembolism guidelines. http://www.surgeons.org/Content/NavigationMenu/FellowshipandStandards/Resourcesforsurgeons/#vt (accessed Mar 2009).
- 5. St George Clinical School, University of New South Wales. Thrombosis information and recommendations for general practitioners and hospital based doctors. http://stgcs.med.unsw.edu.au/stgcsweb.nsf/page/TBD-GP (accessed Mar 2009).
- 6. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 338S-400S.
- 7. Nicolaides AN, Fareed J, Kakkar AK, et al. Prevention and treatment of venous thromboembolism: International Consensus Statement (guidelines according to scientific evidence). Int Angiol 2006; 25: 101-161.
- 8. Baker RI, Coughlin PB, Gallus AS, et al; the Warfarin Reversal Consensus Group. Warfarin reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis and Haemostasis. Med J Aust 2004; 181: 492-497. <MJA full text>
- 9. Ellis P; Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Depression. Australian and New Zealand clinical practice guidelines for the treatment of depression. Aust N Z J Psychiatry 2004; 38: 389-407.
- 10. Sambrook PN, Seeman E, Phillips SR, Ebeling PR; Osteoporosis Australia; National Prescribing Service. Preventing osteoporosis: outcomes of the Australian Fracture Prevention Summit. Med J Aust 2002; 176 (8 Suppl): S1-S16. <MJA full text>
- 11. Krum H, Jelinek MV, Stewart S, et al. Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006. Med J Aust 2006; 185: 549-557. <MJA full text>
- 12. National Health and Medical Research Council. A guide to the development, implementation and evaluation of clinical practice guidelines. Canberra: NHMRC, 1999. http://www.nhmrc.gov.au/publications/synopses/cp30syn.htm (accessed May 2008).
- 13. International Union of Angiology. Members. http://www.i.u.angiology.org/members.html (accessed May 2008).
- 14. Australasian Society of Thrombosis and Haemostasis. Sponsorship. http://www.asth.org.au/sponsorship (accessed May 2008).
- 15. Chong BH, Braithwaite J, Harris MF, Fletcher JP. Venous thromboembolism — a major health and financial burden: how can we do better to prevent this disease [editorial]? Med J Aust 2008; 189: 134-135. <MJA full text>
- 16. Health Education and Management Innovations. The Advanced Wound Care Network: advancing wound care together. http://www.theawcn.org (accessed May 2008).
- 17. Prevention of venous thromboembolism: best practice international guidelines. Sydney: HEMI Australia, 2006.
- 18. Fletcher J, Baker R, MacLellan D, et al. Diagnosis and treatment of venous thromboembolism: best practice guidelines for Australia and New Zealand. Sydney: HEMI, 2004.
- 19. Moynihan R. Drug maker’s PR firm is force behind blood clot awareness. BMJ 2008; 336: 1460.
- 20. Hall L. Simple jab can cut blood clot deaths. Sydney Morning Herald 2008; 24 Feb. http://www.smh.com.au/news/national/simple-jab-can-cut-bloodclot-deaths/2008/02/23/1203467452110.html (accessed May 2008).
- 21. AAP. Clots for 17,000 Aussies a year. Sydney Morning Herald 2008; 4 Aug. http://news.smh.com.au/national/clots-for-17000-aussies-a-year-20080804-3pgh.html (accessed Aug 2008).
- 22. Perth study sounds alarm over blood clots. The West Australian (Perth) 2008; 4 Aug: 4.
- 23. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust 2008; 189: 144-147. <MJA full text>
- 24. Ryan S. Blood clots “more deadly than AIDS”. The Australian 2008; 3 May http://www.theaustralian.news.com.au/story/0,25197,23637356-23289,00.html (accessed May 2008).
- 25. AAP. Blood clots cost Australia $1.72 billion. The West Australian (Perth) 2008; 3 May. http://www.thewest.com.au/aapstory.aspx?StoryName=479598 (accessed May 2008).
- 26. McLean T. Blood clots cost Australia $1.72 billion. Sydney Morning Herald 2008; 3 May. http://news.smh.com.au/blood-clots-cost-australia-172-billion/20080503-2ahs.html (accessed May 2008).
- 27. McLean T. Blood clots cost Australia $1.72 billion. The Age (Melbourne) 2008; 3 May. http://news.theage.com.au/blood-clots-cost-australia-172-billion/20080503-2ahs.html (accessed May 2008).
- 28. Sanofi-Aventis. The Coalition to Prevent Deep-Vein Thrombosis. Bridgewater, NJ: Sanofi-Aventis, 2008. http://www.preventdvt.org (accessed Sep 2008).
- 29. Access Economics The burden of VTE in Australia. Canberra: VTE Taskforce, 2008. http://www.accesseconomics.com.au/publicationsreports/showreport.php?id=161&searchfor=2008&searchby=year (accessed Aug 2008).
- 30. Moynihan R. Public hospital “guidelines” funded by drug maker. Crikey 2008; 17 Apr.
- 31. NSW Health. Venothromboembolism (VTE) surgical and medical management posters and booklet. Sydney: NSW Health, 2008. http://www.health.nsw.gov.au/policies/gl/2008/pdf/GL2008_014.pdf (accessed Sep 2008).
- 32. National Institute of Clinical Studies. VTE prophylaxis audit form. Version 4 2006. http://www.nhmrc.gov.au/nics/programs/_files/2005%20NICS%20VTE% 20Prophylaxis%20Audit%20Form%20v4%20.pdf (accessed Mar 2009).
- 33. Australian Commission on Safety and Quality in Health Care. Reducing blood clot risk for patients. Update 2008; Aug (6): 3. http://www.safetyandquality.gov.au/internet/safety/publishing.nsf/Content/48AA03304E252B17CA 25751600148047/$File/Issue-06.pdf (accessed Mar 2009).
- 34. National Institute for Clinical Studies. Venous thromboembolism prevention program: the evidence base. http://www.nhmrc.gov.au/nics/programs/vtp/venous.htm (accessed Mar 2009).
- 35. National Institute for Clinical Studies. The incidence and risk factors for venous thromboembolism in hospitals in Western Australia 1999 to 2001. Report commissioned from the School of Population Health, University of Western Australia. Canberra: NICS, 2005. http://www.nhmrc.gov.au/nics/material_resources/resources/incident_risk.htm (accessed Mar 2009).
- 36. Roughead EE, Gilbert AL, Primrose JG, Sansom LN. Coding drug-related admissions in medical records: Is it adequate for monitoring the quality of medication use? Aust J Hosp Pharm 1998; 28: 7-12.
- 37. New South Wales Therapeutic Advisory Group. Indicators for quality use of medicines in Australian hospitals 1.2. Percentage of patients at high risk of venous thromboembolism that receive appropriate prophylaxis. Sydney: NSW Therapeutic Advisory Group, 2007. http://www.ciap.health.nsw.gov.au/nswtag/publications/QUMIndicators/1.2.pdf (accessed Mar 2009).
- 38. Western Australian Department of Health Office of Safety and Quality in Healthcare. Clinical Practice Improvement Program. Venous thromboembolism. Perth: The Department, 2007. http://www.safetyandquality.health.wa. gov.au/squire/venous_throm.cfm (accessed Mar 2009).
- 39. National Institute for Clinical Studies. VTE prevention guideline. http://www.nhmrc.gov.au/nics/programs/vtp/prevention.htm (accessed Mar 2009).
- 40. National Institute for Clinical Studies. VTE Prevention Guideline Adaptation Committee. http://www.nhmrc.gov.au/nics/programs/_files/VTE%20 Prevention%20Guideline%20Adaptation%20Committee.pdf (accessed Mar 2009).
- 41. Samama MM, Cohen AT, Darmon J-Y, et al; for the Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med 1999; 341: 793-800.
- 42. Leizorovicz A, Cohen AT, Turpie AGG, et al; for the PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-879.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.